3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Squamous Cell Carcinoma of Head and Neck
3
Melanoma
3
Recurrence
2
Head and Neck Neoplasms
2
Carcinoma, Renal Cell
2
Triple Negative Breast Neoplasms
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Kidney Neoplasms
1
Glioma
1
Ependymoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Interventions
Temozolomide
22
Bevacizumab
10
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Irinotecan
5
Carmustine
4
fluorodopa F 18
3
Topotecan
3
Surgical Procedures, Operative
3
Standard of Care
3
Radiosurgery
3
Magnetic Resonance Imaging
3
Congresses as Topic
3
Carboplatin
3
Aminolevulinic Acid
3
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
3
ribociclib
2
poly ICLC
2
fluoromisonidazole
2
carmustine, poliferprosan 20 drug combination
2
cabozantinib
2
Vorinostat
2
TIC10 compound
2
Re-Irradiation
2
Radiotherapy, Intensity-Modulated
2
Panobinostat
2
O(6)-benzylguanine
2
Melphalan
2
Lomustine
2
Lacosamide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Glioma
×
bempegaldesleukin
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts